GDRX is trading 6.3% down at $2.70 in pre-market, retreating from its recent rebound despite a lack of fresh, stock-specific headlines.
- The move follows previously reported revenue and margin pressure tied to weaker prescription transactions and analyst caution regarding long-term growth.
- Shares remain sensitive to broader risk-off sentiment and lingering concerns about the company's legacy business model.